Physician profile
Marlowe D Ross
NPI 1245244771
$22,375.54
in general payments reported to CMS, 2019-2025
12 companies · $945 in 2025
The $945 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,044 · 2020: $7,920 · 2021: $4,723 · 2022: $5,737 · 2023: $390 · 2024: $616 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,952.83 | 2019-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,259.53 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Glaxosmithkline, LLC. | $1,482.52 | 2019-2025 | Trelegy Ellipta, Nucala |
| Verona Pharma, INC. | $257.94 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $149.99 | 2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Genzyme Corporation | $68.20 | 2025 | |
| Electromed, INC. | $67.25 | 2025 | Smartvest |
| E.R. Squibb & Sons, L.L.C. | $40.81 | 2019-2021 | |
| Genentech USA, INC. | $35.72 | 2021 | |
| Pfizer INC. | $27.61 | 2021 | |
| Mylan Specialty L.P. | $18.57 | 2019 | |
| Circassia INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlowe Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.